Transcript Introducing a New Product

Individualized Medicine
Pharmacogentics
Right Dose. Right Time.
First Time.
Susan Kolyno, BA, CMA,
Vantari Laboratory Representative
[email protected]
Why Pharmacogentics
Avoidable Medical Problem
12
10
2.2 MILLION
700,000
600,000
severe adverse drug reactions per year
8
500,000
Column 3
Column 2
Column 1
6
400.000
300.000
200,000
100,000
PATIENTS ARE AT RISK
4
100,000
2
deaths per year
By PROPERLY PRESCRIBED MEDICATIONS
COST LEADER for Mal-Practice
0
HEA RT
CA NCER
STROKE
RX
CA R CRA SHES
Heart Cancer Stroke RX Car Accidents
Treatment Failures
Prevalent in Disease states
“Keeping in Step”

Cancer
75%

Alzheimers
70%

Arthritis
50%

Diabetic
43%

Asthma
40%

Anti-depressants
38%
“Do No Harm”
GENETIC differences in metabolism = Treatment Failure
Poly-Pharmacy Alzheimer
Complications in Prescribing
Patients Taking More than 3 Medications
AT RISK - 40% are over 65
More than 75% of the population have documented genetic variations that
increase their risk for ADR's.
Medicines most commonly associated with ADR's are
through pathways with genetic variants.
8X more likely to go
Avoiding ADR's
Getting Right the First Time
Pharmacogenetics is the
understanding of how the genetic
variation alters drug response.
Cytochromes (CYPs) are the
metabolic factories in the liver and
intestines.
Poor Metabolizers: Reach maximum
levels very quickly Intermediate
Metabolizers: Half the highway is shut
down, a patient can still metabolize but it is
very difficult. Ultra Metabolizers: Have
additional pathways, these patients never
reach therapeutic effect. Normal
Metabolizers: Have both roads open and
metabolize close to normal.
Changing the Pattern
Will YOU make the Difference?
Interactions involve
cytochromes: 2C9 CYP2D6,
CYP2C19, and CYP3A4
Individual DNA varies in
Medications and Metabolism
Impacting more patients than
Common Genetic testing.
MEDICATION MANAGEMENT
BASED ON PATIENT
METABOLISM
. drug to gene interactions
More than 100 medications have
and are identified in the FDA packet and black box labels
Why Vantari?
Focus IS On the Patient
Vantari centers it's approach on testing
& hard copy results FOR the PATIENT.
Referencing our Partner CPIC, an
independent consortium and 2014 date
publication for physician results & polypharmacy recommendations.
Highly complex CLIA certified.
Getting Started
No Cost Assistance
Complete the simple form with your Vantari
representative:
SET A DATE MONTHLY - Book 10 -15 patients
for an OFF day for screening.
Representative will assist and follow up with
billing or office management.


NO OUT OF POCKET
Compliance Regulated – Request Clinical
Studies, Dossiers, access to CPIC.
Test Results - Insurance
3-5 Days
Your screening tests and follow-up
are billable.
Contact
I can provide case studies, clinical data and insurance
information on pharmacogentics and the impact upon the
medical profession that is NOW changing prescribing
methods rapidly.
Please feel free to contact me with any questions or
individualized studies geared to your practice.
YOUR VANTARI REPRESENTATIVE:
Susan Kolyno
404-989-5084
Website: www.medreferrals.net
RIGHT DOSE. RIGHT TIME. FIRST TIME
YOUR Vantari Team
Accrediations
Nick G. Arroyo -Chief Executive Officer - Nick Arroyo earned his Bachelor of Science Degree in Molecular
Biosciences and Biotechnology from Arizona State University. He began his career working in research in the
Department of Gene and Cellular Therapy at the Arizona Heart Institute where he helped to develop an
investigational stem cell therapy for heart failure and was responsible for the cell manufacturing processes
required for obtaining FDA approval for phase I clinical trial.
Sean Parrish - Chief Operating Officer - Sean Parrish is co-founder of Vantari Genetics and our Chief
Operating Officer. Mr. Parrish's responsibilities encompass national commercialization of our molecular
diagnostics services across the entire value chain from test inception through customer development
and product distribution. Mr. Parrish has been part of the development, launch and marketing strategy
for SimpleCF™, Vantari's cystic fibrosis carrier screening test. Mr. Parrish obtained a Bachelor of
Science degree from the University of Arizona.
Shaun R. Opie, PhDChief Science Officer - Dr. Opie holds a PhD in Biomedical Sciences/Molecular Genetics.
He led all laboratory operations for an investigator initiated Phase I clinical trial using stem cells to treat cardiac
disease and helped develop a proprietary cardiovascular disease gene data set for a publicly traded genomics
company. In addition to clinical trial design and management for FDA regulated investigational new drugs and
devices, Dr. Opie has over 10 years of operations management directing major collaborations with industry and
academic partners in molecular diagnostics research and development. He has held adjunct faculty
appointments in bioengineering and has numerous publications in peer reviewed medical journals and
textbooks.
Phil Lamb -Senior Advisor - Phil has a track record of successfully leading growth businesses into highly
responsive, client-focused service organizations. He provides legal, financial, and strategic advice to the Vantari
Genetic team. In addition to his role with Vantari Genetics, he is also a principal in Infinity Software Solutions, a
leading Human Resources Information System (HRIS). Phil received his J.D. from Harvard Law.
Thank You
Right Dose. Right Time.
First Time.
Preventative Patient Care
Susan Kolyno, Account Manager, Vantari Laboratories
423-790-7306 or 404-989-5084